Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u‐HCC) patients classified as Child‐Pugh A (CP‐A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially CP‐A and ‐B cases.

[1]  J. Bruix,et al.  Reply to: "Correspondence on the ". , 2022, Journal of hepatology.

[2]  P. Galle,et al.  Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis. , 2022, Journal of Clinical Oncology.

[3]  M. Moriguchi,et al.  Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma , 2021, Liver Cancer.

[4]  M. Kudo,et al.  Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  Myung Ah Lee,et al.  Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[6]  M. Morimoto,et al.  Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  Y. Hirooka,et al.  Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma , 2021, Oncology.

[8]  H. Seno,et al.  Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma , 2021, Current oncology.

[9]  M. Kurosaki,et al.  Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice , 2021, Investigational New Drugs.

[10]  T. Miyagishima,et al.  Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  H. Koga,et al.  Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice , 2021, Cancers.

[12]  M. Kudo,et al.  Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  A. Hiraoka,et al.  Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database , 2021, Drugs - Real World Outcomes.

[14]  H. Lee,et al.  Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study , 2021, Liver Cancer.

[15]  M. Moriguchi,et al.  Transition of molecular target agent therapy in advanced hepatocellular carcinoma: A multicenter, retrospective study. , 2021 .

[16]  K. Shirabe,et al.  The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study , 2020, Oncology.

[17]  M. Imamura,et al.  Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib , 2020, Oncology.

[18]  M. Kudo,et al.  A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements , 2020, Liver Cancer.

[19]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[20]  S. Mochida,et al.  Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome , 2020, PloS one.

[21]  M. Kudo,et al.  Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma , 2020, Oncology.

[22]  M. Kudo,et al.  Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma , 2019, Oncology.

[23]  M. Kudo,et al.  Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis , 2019, Cancer medicine.

[24]  M. Kudo,et al.  Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein. , 2019, The Lancet. Oncology.

[25]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[26]  M. Kudo,et al.  Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis , 2018, Liver Cancer.

[27]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[28]  M. Kudo,et al.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.

[29]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[30]  M. Honda,et al.  Post‐progression survival and progression‐free survival in patients with advanced hepatocellular carcinoma treated by sorafenib , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[31]  H. Toyoda,et al.  Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma , 2016, Journal of gastroenterology and hepatology.

[32]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Kudo,et al.  Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update , 2014, Oncology.

[34]  Sahil Mittal,et al.  Epidemiology of hepatocellular carcinoma: consider the population. , 2013, Journal of clinical gastroenterology.

[35]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[36]  T. Roskams,et al.  EASL clinical practical guidelines: management of alcoholic liver disease. , 2012, Journal of hepatology.

[37]  U. Motosugi,et al.  Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. , 2011, Radiology.

[38]  C. Catalano,et al.  Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. , 2010, Radiology.

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[40]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[41]  Haesook T. Kim.  Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.

[42]  Chaofeng Liu,et al.  Adjusted Kaplan–Meier estimator and log‐rank test with inverse probability of treatment weighting for survival data , 2005, Statistics in medicine.

[43]  M. Kudo,et al.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) , 2003, Journal of Gastroenterology.

[44]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[45]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[46]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[47]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .